Efficacy of Formulated Posterior Subtenon Triamcinolone in Macular Edema secondary to Non–Ischemic Retinal Vein Occlusions

Background: Retinal vein occlusion [RVO] is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema, which may be treated by triamcinolone.The Aim of the work: To detect the efficacy of formulated Triamcinolo...

Full description

Bibliographic Details
Main Authors: Ehab Tharwat, Akram Elgazar, Riad Hassan Ahmed
Format: Article
Language:English
Published: Al-Azhar University, Faculty of Medicine (Damietta) 2022-06-01
Series:International Journal of Medical Arts
Subjects:
Online Access:https://ijma.journals.ekb.eg/article_252900_caa6d9ad98963a655f64c068188e8257.pdf
_version_ 1797364447536218112
author Ehab Tharwat
Akram Elgazar
Riad Hassan Ahmed
author_facet Ehab Tharwat
Akram Elgazar
Riad Hassan Ahmed
author_sort Ehab Tharwat
collection DOAJ
description Background: Retinal vein occlusion [RVO] is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema, which may be treated by triamcinolone.The Aim of the work: To detect the efficacy of formulated Triamcinolone Acetonide [TA] injection in the posterior subtenon space to manage macular edema secondary to non-ischemic RVOs, either central or branch.Patients and methods: Our study included forty-six eyes from 46 patients with non-ischemic RVO. All the eyes received a single dose of 40 mg of Triamcinolone Acetonide [TA] and VISCOAT, which is 20 mg sodium chondroitin sulfate and 15 mg sodium hyaluronate [0.5 ml] through the posterior subtenon route using NAGATA subtenon canula. Complete ophthalmic examinations were done at the baseline and after one, three, and six months of injections.Result: The mean age of patients was 58.28±5.19 years. BCVA increased from 0.40 [0.10-0.70] at baseline to 0.75 [0.10-1.00] at the 1st ,3rd and 6th month [P < 0.001]. The median baseline OCT thickness changed from 411.50 [294.00-624.00] μm pre-injection to 265.00[187.00-614.00] μm [1st month], 265.00 [187.00-614.00] μm [3rd month], and 209.00 [178.00-531.00] m [6th month] [p<0.001]. The median IOP decreased from 13.00 [11.00-18.00] mm Hg on initial assessment to 12.00 [10.00-16.00] at the end of the study without any elevation at any point.Conclusion: Formulated posterior subtenon triamcinolone acetonide [PSTA] is an effective treatment for macular edema secondary to Non- Ischemic RVO with minimal complications.
first_indexed 2024-03-08T16:35:29Z
format Article
id doaj.art-9f6937b887f742899d1da4106573f4f9
institution Directory Open Access Journal
issn 2636-4174
2682-3780
language English
last_indexed 2024-03-08T16:35:29Z
publishDate 2022-06-01
publisher Al-Azhar University, Faculty of Medicine (Damietta)
record_format Article
series International Journal of Medical Arts
spelling doaj.art-9f6937b887f742899d1da4106573f4f92024-01-05T19:39:33ZengAl-Azhar University, Faculty of Medicine (Damietta)International Journal of Medical Arts2636-41742682-37802022-06-01462440244710.21608/ijma.2022.149628.1482252900Efficacy of Formulated Posterior Subtenon Triamcinolone in Macular Edema secondary to Non–Ischemic Retinal Vein OcclusionsEhab Tharwat0Akram Elgazar1Riad Hassan Ahmed2Department of Ophthalmology, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.Department of Ophthalmology, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.Department of Ophthalmology, Faculty of Medicine, Al-Azhar University, Damietta, Egypt.Background: Retinal vein occlusion [RVO] is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema, which may be treated by triamcinolone.The Aim of the work: To detect the efficacy of formulated Triamcinolone Acetonide [TA] injection in the posterior subtenon space to manage macular edema secondary to non-ischemic RVOs, either central or branch.Patients and methods: Our study included forty-six eyes from 46 patients with non-ischemic RVO. All the eyes received a single dose of 40 mg of Triamcinolone Acetonide [TA] and VISCOAT, which is 20 mg sodium chondroitin sulfate and 15 mg sodium hyaluronate [0.5 ml] through the posterior subtenon route using NAGATA subtenon canula. Complete ophthalmic examinations were done at the baseline and after one, three, and six months of injections.Result: The mean age of patients was 58.28±5.19 years. BCVA increased from 0.40 [0.10-0.70] at baseline to 0.75 [0.10-1.00] at the 1st ,3rd and 6th month [P < 0.001]. The median baseline OCT thickness changed from 411.50 [294.00-624.00] μm pre-injection to 265.00[187.00-614.00] μm [1st month], 265.00 [187.00-614.00] μm [3rd month], and 209.00 [178.00-531.00] m [6th month] [p<0.001]. The median IOP decreased from 13.00 [11.00-18.00] mm Hg on initial assessment to 12.00 [10.00-16.00] at the end of the study without any elevation at any point.Conclusion: Formulated posterior subtenon triamcinolone acetonide [PSTA] is an effective treatment for macular edema secondary to Non- Ischemic RVO with minimal complications.https://ijma.journals.ekb.eg/article_252900_caa6d9ad98963a655f64c068188e8257.pdfretinal vein occlusionposterior subtenontriamcinolonemacular edema
spellingShingle Ehab Tharwat
Akram Elgazar
Riad Hassan Ahmed
Efficacy of Formulated Posterior Subtenon Triamcinolone in Macular Edema secondary to Non–Ischemic Retinal Vein Occlusions
International Journal of Medical Arts
retinal vein occlusion
posterior subtenon
triamcinolone
macular edema
title Efficacy of Formulated Posterior Subtenon Triamcinolone in Macular Edema secondary to Non–Ischemic Retinal Vein Occlusions
title_full Efficacy of Formulated Posterior Subtenon Triamcinolone in Macular Edema secondary to Non–Ischemic Retinal Vein Occlusions
title_fullStr Efficacy of Formulated Posterior Subtenon Triamcinolone in Macular Edema secondary to Non–Ischemic Retinal Vein Occlusions
title_full_unstemmed Efficacy of Formulated Posterior Subtenon Triamcinolone in Macular Edema secondary to Non–Ischemic Retinal Vein Occlusions
title_short Efficacy of Formulated Posterior Subtenon Triamcinolone in Macular Edema secondary to Non–Ischemic Retinal Vein Occlusions
title_sort efficacy of formulated posterior subtenon triamcinolone in macular edema secondary to non ischemic retinal vein occlusions
topic retinal vein occlusion
posterior subtenon
triamcinolone
macular edema
url https://ijma.journals.ekb.eg/article_252900_caa6d9ad98963a655f64c068188e8257.pdf
work_keys_str_mv AT ehabtharwat efficacyofformulatedposteriorsubtenontriamcinoloneinmacularedemasecondarytononischemicretinalveinocclusions
AT akramelgazar efficacyofformulatedposteriorsubtenontriamcinoloneinmacularedemasecondarytononischemicretinalveinocclusions
AT riadhassanahmed efficacyofformulatedposteriorsubtenontriamcinoloneinmacularedemasecondarytononischemicretinalveinocclusions